Brain cholesterol metabolism and neurologic disease

Neurology

Volumn 71, Issue 17, 2008, Pages 1368-1373

  Benarroch, Eduardo E ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

7 DEHYDROCHOLESTEROL; ABC TRANSPORTER A1; AMYLOID PRECURSOR PROTEIN; APOLIPOPROTEIN E; CHOLESTANETRIOL 26 MONOOXYGENASE; CHOLESTEROL; MEVALONATE KINASE; OXYSTEROL; PROTEIN; SONIC HEDGEHOG PROTEIN; STEROID; STEROL 27 HYDROXYLASE;

ALZHEIMER DISEASE; ASTROCYTE; BRAIN; BRAIN DEVELOPMENT; CEREBROTENDINOUS XANTHOMATOSIS; CHOLESTEROL METABOLISM; CHOLESTEROL SYNTHESIS; CLINICAL FEATURE; COVALENT BOND; DRUG BIOAVAILABILITY; GENE MUTATION; GENETIC TRANSCRIPTION; GENOTYPE PHENOTYPE CORRELATION; HUMAN; HUNTINGTON CHOREA; LIPID RAFT; MEVALONATE KINASE DEFICIENCY; MYELIN SHEATH; NERVE CELL; NERVE CELL PLASTICITY; NERVE FUNCTION; NEUROLOGIC DISEASE; NIEMANN PICK DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; SMITH LEMLI OPITZ SYNDROME; TANGIER DISEASE; ANIMAL; GENETICS; LIPID METABOLISM; METABOLISM; PATHOLOGY; PHYSIOLOGY;

ANIMALS; BRAIN; CHOLESTEROL; HUMANS; LIPID METABOLISM; NERVOUS SYSTEM DISEASES;

EID: 55449116793     PISSN: 00283878     EISSN: 1526632X     Source Type: Journal    
DOI: 10.1212/01.wnl.0000333215.93440.36     Document Type: Article

References (40)

1. Pfrieger FW. Cholesterol homeostasis and function in neurons of the central nervous system. Cell Mol Life Sci 2003; 60:1158-1171.
2. Vaya J, Schipper HM. Oxysterols, cholesterol homeostasis, and Alzheimer disease. J Neurochem 2007;102:1727-1737.
3. Canevari L, Clark JB. Alzheimer's disease and cholesterol: the fat connection. Neurochem Res 2007;32:739-750.
4. Dietschy JM, Turley SD. Thematic review series: brain lipids: cholesterol metabolism in the central nervous system during early development and in the mature animal. J Lipid Res 2004;45:1375-1397.
5. Sevin M, Lesca G, Baumann N, et al. The adult form of Niemann-Pick disease type C. Brain 2007;130(Pt 1):120- 133.
6. Porter FD. Smith-Lemli-Opitz syndrome: pathogenesis, diagnosis and management. Eur J Hum Genet 2008;16: 535-541.
7. Gallus GN, Dotti MT, Federico A. Clinical and molecular diagnosis of cerebrotendinous xanthomatosis with a review of the mutations in the CYP27A1 gene. Neurol Sci 2006; 27:143-149.
8. Kolovou GD, Mikhailidis DP, Anagnostopoulou KK, Daskalopoulou SS, Cokkinos DV. Tangier disease four decades of research: a reflection of the importance of HDL. Curr Med Chem 2006;13:771-782.
9. Lane RM, Farlow MR. Lipid homeostasis and apolipopro-tein E in the development and progression of Alzheimer's disease. J Lipid Res 2005;46:949-968.
10. Huang Y. Apolipoprotein E and Alzheimer disease. Neurology 2006;66(2 suppl 1):S79-85.
11. Beffert U, Danik M, Krzywkowski P, Ramassamy C, Berrada F, Poirier J. The neurobiology of apolipoproteins and their receptors in the CNS and Alzheimer's disease. Brain Res Brain Res Rev 1998;27:119-142.
12. Valenza M, Cattaneo E. Cholesterol dysfunction in neuro-degenerative diseases: is Huntington's disease in the list? Prog Neurobiol 2006;80:165-176.
13. Allen JA, Halverson-Tamboli RA, Rasenick MM. Lipid raft microdomains and neurotransmitter signalling. Nat Rev Neurosci 2007;8:128-140.
14. Maxfield FR, Tabas I. Role of cholesterol and lipid organization in disease. Nature 2005;438:612-621.
15. Herz J, Bock HH. Lipoprotein receptors in the nervous system. Annu Rev Biochem 2002;71:405-434.
16. Burris TP, Eacho PI, Cao G. Genetic disorders associated with ATP binding cassette cholesterol transporters. Mol Genet Metab. 2002;77:13-20.
17. Zarubica A, Trompier D, Chimini G. ABCA1, from pathology to membrane function. Pflugers Arch 2007;453: 569-579.
18. Sleat DE, Wiseman JA, El-Banna M, et al. Genetic evidence for nonredundant functional cooperativity between NPC1 and NPC2 in lipid transport. Proc Natl Acad Sci USA 2004;101:5886-5891.
19. Bjorkhem I, Lutjohann D, Diczfalusy U, Stahle L, Ahlborg G, Wahren J. Cholesterol homeostasis in human brain: turnover of 24S-hydroxycholesterol and evidence for a cerebral origin of most of this oxysterol in the circulation. J Lipid Res 1998;39:1594-1600.
20. Herz J, Chen Y. Reelin, lipoprotein receptors and synaptic plasticity. Nat Rev Neurosci 2006;7:850-859.
21. Kotti TJ, Ramirez DM, Pfeiffer BE, Huber KM, Russell DW. Brain cholesterol turnover required for geranylge-raniol production and learning in mice. Proc Natl Acad Sci USA 2006;103:3869-3874.
22. May P, Rohlmann A, Bock HH, et al. Neuronal LRP1 functionally associates with postsynaptic proteins and is required for normal motor function in mice. Mol Cell Biol 2004;24:8872-8883.
23. Mahley RW, Weisgraber KH, Huang Y. Apolipoprotein E4: a causative factor and therapeutic target in neuropa-thology, including Alzheimer's disease. Proc Natl Acad Sci USA 2006;103:5644-5651.
24. Wang L, Schuster GU, Hultenby K, Zhang Q, Andersson S, Gustafsson JA. Liver X receptors in the central nervous system: from lipid homeostasis to neuronal degeneration. Proc Natl Acad Sci USA 2002;99:13878-13883.
25. Patterson MC. A riddle wrapped in a mystery: understanding Niemann-Pick disease, type C. Neurologist 2003;9:301-310.
26. Pietrini V, Rizzuto N, Vergani C, Zen F, Ferro Milone F. Neuropathy in Tangier disease: a clinicopathologic study and a review of the literature. Acta Neurol Scand 1985;72:495- 505.
27. Burns M, Duff K. Use of in vivo models to study the role of cholesterol in the etiology of Alzheimer's disease. Neu-rochem Res 2003;28:979-986.
28. Wahrle S, Das P, Nyborg AC, et al. Cholesterol-dependent gamma-secretase activity in buoyant cholesterol-rich membrane microdomains. Neurobiol Dis 2002;9:11-23.
29. Kojro E, Gimpl G, Lammich S, Marz W, Fahrenholz F. Low cholesterol stimulates the nonamyloidogenic pathway by its effect on the alpha-secretase ADAM 10. Proc Natl Acad Sci USA 2001;98:5815-5820.
30. Subasinghe S, Unabia S, Barrow CJ, Mok SS, Aguilar MI, Small DH. Cholesterol is necessary both for the toxic effect of Abeta peptides on vascular smooth muscle cells and for Abeta binding to vascular smooth muscle cell membranes. J Neurochem 2003;84:471-479.
31. Curtain CC, Ali FE, Smith DG, Bush AI, Masters CL, Barnham KJ. Metal ions, pH, and cholesterol regulate the interactions of Alzheimer's disease amyloid-beta peptide with membrane lipid. J Biol Chem 2003;278:2977-2982.
32. Nagy Z, Esiri MM, Jobst KA, et al. Influence of the apolipoprotein E genotype on amyloid deposition and neurofibrillary tangle formation in Alzheimer's disease. Neuroscience 1995;69:757-761.
33. Gibson GE, Haroutunian V, Zhang H, et al. Mitochon-drial damage in Alzheimer's disease varies with apolipoprotein E genotype. Ann Neurol 2000;48:297-303.
34. Michikawa M, Fan QW, Isobe I, Yanagisawa K. Apoli-poprotein E exhibits isoform-specific promotion of lipid efflux from astrocytes and neurons in culture. J Neuro-chem 2000;74:1008-1016.
35. Stratman NC, Castle CK, Taylor BM, Epps DE, Melchior GW, Carter DB. Isoform-specific interactions of human apolipoprotein E to an intermediate conformation of human Alzheimer amyloid-beta peptide. Chem Phys Lipids 2005;137:52-61.
36. Brown J, 3rd, Theisler C, Silberman S, et al. Differential expression of cholesterol hydroxylases in Alzheimer's disease. J Biol Chem 2004;279:34674-34681.
37. Papassotiropoulos A, Lutjohann D, Bagli M, et al. Plasma 24S-hydroxycholesterol: a peripheral indicator of neuronal degeneration and potential state marker for Alzheimer's disease. Neuroreport 2000;11:1959-1962.
38. Chang JY, Liu LZ. Neurotoxicity of cholesterol oxides on cultured cerebellar granule cells. Neurochem Int 1998;32: 317-323.
39. Koldamova RP, Lefterov IM, Staufenbiel M, et al. The liver X receptor ligand T0901317 decreases amyloid beta production in vitro and in a mouse model of Alzheimer's disease. J Biol Chem 2005;280:4079- 4088.
40. Liu B, Li H, Repa JJ, Turley SD, Dietschy JM. Genetic variations and treatments that affect the lifespan of the NPC1 mouse. J Lipid Res 2008;49: 663-669.